Skip to main content
Erschienen in: Journal of Clinical Immunology 3/2022

18.01.2022 | Letter to Editor

A De Novo Cause of PGM3 Deficiency Treated with Hematopoietic Stem Cell Transplantation

verfasst von: Andrew Winslow, Elizabeth R. Jalazo, April Evans, Mike Winstead, Timothy Moran

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Literatur
1.
Zurück zum Zitat Sassi A, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol. 2014;133(5):1410-9-1419.e1-13.CrossRef Sassi A, et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol. 2014;133(5):1410-9-1419.e1-13.CrossRef
2.
Zurück zum Zitat Zhang Y, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol. 2014;133(5):1400-9-1409.e1-5.CrossRef Zhang Y, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol. 2014;133(5):1400-9-1409.e1-5.CrossRef
3.
Zurück zum Zitat Stray-Pedersen A, et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet. 2014;95(1):96–107.CrossRefPubMedPubMedCentral Stray-Pedersen A, et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet. 2014;95(1):96–107.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Lundin KE, et al. Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene. Clin Immunol. 2015;161(2):366–72.CrossRefPubMedPubMedCentral Lundin KE, et al. Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene. Clin Immunol. 2015;161(2):366–72.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Fusaro M, et al. Two novel homozygous mutations in phosphoglucomutase 3 leading to severe combined immunodeficiency, skeletal dysplasia, and malformations. J Clin Immunol. 2021;41(5):958–66.CrossRefPubMed Fusaro M, et al. Two novel homozygous mutations in phosphoglucomutase 3 leading to severe combined immunodeficiency, skeletal dysplasia, and malformations. J Clin Immunol. 2021;41(5):958–66.CrossRefPubMed
6.
Zurück zum Zitat García-García A, et al. Novel PGM3 compound heterozygous variants with IgE-related dermatitis, lymphopenia, without syndromic features. Pediatr Allergy Immunol. 2021;32(3):566–75.CrossRefPubMed García-García A, et al. Novel PGM3 compound heterozygous variants with IgE-related dermatitis, lymphopenia, without syndromic features. Pediatr Allergy Immunol. 2021;32(3):566–75.CrossRefPubMed
Metadaten
Titel
A De Novo Cause of PGM3 Deficiency Treated with Hematopoietic Stem Cell Transplantation
verfasst von
Andrew Winslow
Elizabeth R. Jalazo
April Evans
Mike Winstead
Timothy Moran
Publikationsdatum
18.01.2022
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 3/2022
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01196-z

Weitere Artikel der Ausgabe 3/2022

Journal of Clinical Immunology 3/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.